The Krannert Cardiovascular Research Center at the Indiana University School of Medicine recently released its Three-Year Impact Report that showcases its achievements in expanding the cardiovascular research program from 2021 to 2024.
Within this short period, IU Krannert:
- Increased its grant funding from $1.1 million annually to $22 million annually
- Revamped the cardiovascular clinical trials research program
- Hosted the two-day Krannert Biennial, which brought to Indianapolis renowned cardiovascular researchers from around the world
- Launched the first-in-human FDA-approved investigative clinical trial targeting ST Elevation Myocardial Infarction
- Introduced the world’s first classification of heart attacks based on tissue damage, which has been adopted by the Canadian Cardiovascular Society.
“Much of our success is due to the dedication of our investigative team, students and staff who aspire to advance cardiovascular research and clinical care to benefit the next generation, as well as the many partners and collaborators we have located worldwide,” said Rohan Dharmakumar, PhD, executive director of the Krannert Cardiovascular Research Center and vice chair of the Department of Radiology and Imaging Sciences.
The report includes updates from Rohan Dharmakumar, PhD, Ischemic Heart Disease Research; Ankit A. Desai, MD, Cardiopulmonary Research; Khadijah Breathett, MD, Cardiovascular Equity Research; Thomas H. Everett, PhD and Zhenhui Chen, PhD, Electrophysiology Research; Suparna C. Clasen, MD, Cardiovascular Clinical Research; Behzad Sharif, PhD, Microcirculation Research; Loren J. Field, PhD, Myocardial Regenerative Biology Research; and Bohdan Khomtchouk, PhD, Cardioinformatics Research. It also highlights early investigators, significant milestones and the Krannert Biennial with a photo gallery.